Coverage
-
May 03, 2013
The 11th Circuit refused Thursday to let a Florida hospital appeal in hopes of winning certification of an $867 million antitrust class action accusing Astellas Pharma Inc. of improperly requiring use of its Adenoscan drug with patented cardiac tests, but the provider intends to soldier on alone.
5 other articles on this case.
View all »